Coherus Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Coherus BioSciences
CHRS Stock  USD 0.88  0.03  3.53%   
Coherus BioSciences financial statements provide useful quarterly and yearly information to potential Coherus BioSciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Coherus BioSciences financial statements helps investors assess Coherus BioSciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Coherus BioSciences' valuation are summarized below:
Gross Profit
-58.4 M
Profit Margin
(0.1)
Market Capitalization
101.7 M
Enterprise Value Revenue
0.6886
Revenue
308.1 M
There are over one hundred nineteen available fundamental signals for Coherus BioSciences, which can be analyzed over time and compared to other ratios. All traders should validate Coherus BioSciences' prevailing fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 518.3 M in 2024, whereas Enterprise Value is likely to drop slightly above 539.3 M in 2024.

Coherus BioSciences Total Revenue

172.86 Million

Check Coherus BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coherus BioSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 42.6 M or Selling General Administrative of 100.1 M, as well as many indicators such as Price To Sales Ratio of 1.16, Dividend Yield of 0.0 or Days Sales Outstanding of 388. Coherus financial statements analysis is a perfect complement when working with Coherus BioSciences Valuation or Volatility modules.
  
Check out the analysis of Coherus BioSciences Correlation against competitors.
For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.

Coherus BioSciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding54.8 M94.2 M47 M
Slightly volatile
Total Assets362.5 M629.6 M291.3 M
Slightly volatile
Short and Long Term Debt Total248.2 M480.8 M180.7 M
Slightly volatile
Other Current Liabilities309.1 M294.4 M64.1 M
Slightly volatile
Total Current Liabilities348.4 M331.8 M91.6 M
Slightly volatile
Other Liabilities3.8 M4 M28.2 M
Very volatile
Property Plant And Equipment Net10.3 M11 M8.4 M
Slightly volatile
Accounts Payable18.7 M35.2 M15.3 M
Slightly volatile
Cash182.4 M102.9 M146.7 M
Slightly volatile
Non Current Assets Total161.7 M154 M48.4 M
Slightly volatile
Non Currrent Assets Other74.4 M70.8 M27.7 M
Slightly volatile
Other Assets77.5 M73.8 M25.1 M
Slightly volatile
Cash And Short Term Investments195.5 M117.7 M157.1 M
Slightly volatile
Common Stock Total Equity5.6 K9.2 K4.9 K
Slightly volatile
Liabilities And Stockholders Equity362.5 M629.6 M291.3 M
Slightly volatile
Non Current Liabilities Total288.9 M491.3 M230.2 M
Slightly volatile
Other Current Assets36.5 M34.8 M11.5 M
Slightly volatile
Other Stockholder Equity785.7 M1.4 B623.9 M
Slightly volatile
Total Liabilities864.2 M823 M310.8 M
Slightly volatile
Property Plant And Equipment Gross15.1 M25.8 M12.2 M
Slightly volatile
Total Current Assets311.1 M475.6 M250.3 M
Slightly volatile
Short Term Debt4.2 M2.1 M4.5 M
Very volatile
Common Stock6.1 K11 K5 K
Slightly volatile
Property Plant Equipment102.7 M97.8 M31 M
Slightly volatile
Good Will751 K943 K927.3 K
Slightly volatile
Capital Surpluse900.6 M1.4 B711.3 M
Slightly volatile
Short and Long Term Debt199.2 K209.7 K664.9 K
Slightly volatile
Non Current Liabilities Other10.9 M11.5 M41.7 M
Pretty Stable
Intangible Assets74.3 M70.7 M12.1 M
Slightly volatile
Long Term Debt Total230.6 M259.4 M170.6 M
Slightly volatile
Net Invested Capital343.9 M279.9 M231.1 M
Slightly volatile
Net Working Capital136.7 M143.9 M194.3 M
Slightly volatile
Capital Stock8.6 K11 K7.4 K
Slightly volatile
Capital Lease Obligations7.6 M7.5 M9.8 M
Slightly volatile

Coherus BioSciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2 M3.8 M1.6 M
Slightly volatile
Interest Expense42.6 M40.5 M14.6 M
Slightly volatile
Selling General Administrative100.1 M192 M80.2 M
Slightly volatile
Total Revenue172.9 M257.2 M137.5 M
Slightly volatile
Gross Profit141.2 M94.5 M112.4 M
Slightly volatile
Other Operating Expenses297.4 M450.4 M241.5 M
Slightly volatile
Research Development163.7 M102 M134.6 M
Slightly volatile
Cost Of Revenue83.5 M162.8 M94.4 M
Pretty Stable
Total Operating Expenses265.8 M287.7 M216.4 M
Slightly volatile
Interest Income21.3 M20.2 M9.3 M
Slightly volatile
Reconciled Depreciation3.7 M3.8 M3.4 M
Slightly volatile
Selling And Marketing Expenses7.6 M12.1 M5.8 M
Slightly volatile

Coherus BioSciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation31.7 M43.1 M25.2 M
Slightly volatile
Begin Period Cash Flow60.4 M63.5 M131.5 M
Slightly volatile
Depreciation2.7 M3.8 M2.2 M
Slightly volatile
Capital Expenditures271.7 K286 K3.4 M
Very volatile
Total Cash From Financing Activities121.3 M69.6 M99.9 M
Pretty Stable
End Period Cash Flow182.6 M102.9 M146.9 M
Slightly volatile
Change To Netincome68.6 M95.4 M56.4 M
Slightly volatile
Issuance Of Capital Stock36 M71.7 M74.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.161.218978.3829
Slightly volatile
Stock Based Compensation To Revenue0.160.16763.2627
Very volatile
Capex To Depreciation0.07170.07542.9259
Slightly volatile
Payables Turnover6.614.6226.4377
Slightly volatile
Sales General And Administrative To Revenue0.760.88.2291
Very volatile
Research And Ddevelopement To Revenue0.380.396717.0691
Pretty Stable
Capex To Revenue0.00110.00110.4531
Slightly volatile
Cash Per Share1.191.25053.6189
Very volatile
Days Payables Outstanding75.0278.9698205
Pretty Stable
Intangibles To Total Assets0.120.11380.0303
Slightly volatile
Current Ratio1.361.43363.4756
Slightly volatile
Graham Number12.8510.805810.8081
Very volatile
Capex Per Share0.00290.0030.0945
Slightly volatile
Revenue Per Share2.062.73192.2185
Slightly volatile
Interest Debt Per Share5.755.48052.8247
Slightly volatile
Debt To Assets0.390.75530.4235
Slightly volatile
Days Of Payables Outstanding75.0278.9698205
Pretty Stable
Ebt Per Ebit1.21.23331.0647
Pretty Stable
Long Term Debt To Capitalization1.781.69091.0095
Slightly volatile
Quick Ratio1.181.24492.9616
Slightly volatile
Net Income Per E B T0.810.99840.9952
Pretty Stable
Cash Ratio0.290.31012.2068
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.091.00161.0088
Pretty Stable
Fixed Asset Turnover24.4923.320112.7981
Slightly volatile
Debt Ratio0.390.75530.4235
Slightly volatile
Price Sales Ratio1.161.218978.3829
Slightly volatile
Asset Turnover0.290.40860.315
Slightly volatile

Coherus BioSciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap518.3 M313.6 M571.2 M
Slightly volatile

Coherus Fundamental Market Drivers

Forward Price Earnings6.7981
Cash And Short Term Investments117.7 M

Coherus Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Coherus BioSciences Financial Statements

Coherus BioSciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Coherus BioSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Coherus BioSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coherus BioSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.8 M-2.7 M
Total Revenue257.2 M172.9 M
Cost Of Revenue162.8 M83.5 M
Stock Based Compensation To Revenue 0.17  0.16 
Sales General And Administrative To Revenue 0.80  0.76 
Research And Ddevelopement To Revenue 0.40  0.38 
Revenue Per Share 2.73  2.06 
Ebit Per Revenue(0.75)(0.79)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Coherus Stock Analysis

When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY